Physician profile
Saud Alvi
NPI 1609031509
$3,556.71
in general payments reported to CMS, 2019-2025
25 companies · $773 in 2025
The $773 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $124 · 2021: $679 · 2022: $467 · 2023: $726 · 2024: $540 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.34 |
| Education | $229.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $535.59 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Abbvie INC. | $507.64 | 2020-2025 | Rinvoq |
| Janssen Biotech, INC. | $445.62 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $290.49 | 2019-2025 | Orencia |
| Pfizer INC. | $290.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $271.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $198.77 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $197.44 | 2021-2025 | Saphnelo |
| Ucb, INC. | $124.23 | 2021-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $96.19 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $87.11 | 2022-2025 | Acthar |
| Genentech USA, INC. | $69.16 | 2019-2025 | Gazyva |
| Genzyme Corporation | $57.19 | 2023-2025 | |
| Organon LLC | $49.89 | 2021-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $49.05 | 2023-2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.89 | 2022-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.76 | 2023-2024 | Cyltezo |
| Antares Pharma, INC. | $42.29 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $36.31 | 2021-2023 | Lupkynis |
| Sobi, INC | $29.99 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $22.22 | 2024 | Arcalyst |
| Ani Pharmaceuticals, INC. | $18.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.39 | 2021 | |
| Sonex Health, INC. | $16.74 | 2025 | Sx-One Microknife |
| Hikma Pharmaceuticals USA | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saud Alvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.